CVE:ZMDZoomMed Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ZoomMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume290,486 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartCompetitorsEarningsHeadlinesSocial Media ZoomMed Inc., together with its subsidiaries, develops and markets a range of computer applications designed for healthcare professionals primarily in the United States and the United Kingdom. The company builds and operates a clinical information exchange platform between physicians, pharmacists, and various other stakeholders of the healthcare sector, such as pharmacists, specialists, pharmaceutical companies, laboratories, physiotherapy clinics, and other organizations. It also offers ZRx Prescriber, a technological Web application that enables physicians to generate prescriptions. ZoomMed Inc. was incorporated in 2005 and is headquartered in Brossard, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for ZoomMed. Previous Next 2.2 Community Rank Outperform VotesZoomMed has received 46 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZoomMed has received 57 “underperform” votes. (Add your “underperform” vote.)Community SentimentZoomMed has received 55.34% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ZoomMed and other stocks. Vote “Outperform” if you believe ZMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZoomMed does not currently pay a dividend.Dividend GrowthZoomMed does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ZoomMed insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ZoomMed is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ZoomMed is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.44 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Health Information Services Sub-IndustryN/A SectorComputer and Technology Current SymbolCVE:ZMD Previous Symbol CUSIPN/A CIKN/A Webzoommedcorpo.com Phone+1-450-6785457Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$10,000.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueC($0.02) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable 30 days | 90 days | 365 days | Advanced Chart Receive ZMD News and Ratings via Email Sign-up to receive the latest news and ratings for ZMD and its competitors with MarketBeat's FREE daily newsletter. ZoomMed (CVE:ZMD) Frequently Asked Questions Has ZoomMed been receiving favorable news coverage? News stories about ZMD stock have trended negative on Thursday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ZoomMed earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about ZoomMed. Who are some of ZoomMed's key competitors? Some companies that are related to ZoomMed include CannaOne Technologies (CNNA), CannaOne Technologies (CNONF), CloudMD Software & Services (DOC), Corum Group (COO), eWELLNESS HEALTHCARE (EWLL), NMC Health (PMCUF), Omnicell (MTHRF), Opyl (OPL), Painchek (PCK), PKS (PKS), Tali Digital (TD1), US-China Biomedical Technology (UCBB) and WELL Health Technologies (WLYYF). View all competitors. Who are ZoomMed's key executives? ZoomMed's management team includes the following people: Mr. Yves Marmet, Chairman, CEO & PresMs. Marie-Helene Pinard, CFO, VP of Operations & Fin., Sec. and DirectorMr. André Marmet, VP of Corp. Bus. What is ZoomMed's stock symbol? ZoomMed trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ZMD." How do I buy shares of ZoomMed? Shares of ZMD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is ZoomMed's official website? The official website for ZoomMed is zoommedcorpo.com. How can I contact ZoomMed? ZoomMed's mailing address is 8005 du Quartier Blvd Suite 303, BROSSARD, QC J4Y 0N5, Canada. The company can be reached via phone at +1-450-6785457. This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
